Dr. Lal PathLabs (LALPATHLAB) | Stock Overview & Key Data
Dr. Lal PathLabs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹4,245.50 on September 13, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dr. Lal PathLabs
LALPATHLAB
|
238.92B Large-cap | 4.53% | 0.82% | 20.51% | 13.04% | 7.03% | 8.45% | 58.06% | 0.84% | 257.00% | 257.46% | 257.46% |
|
Sai Life Sciences
SAILIFE
|
217.06B Large-cap | 1.11% | 10.73% | 23.70% | 32.85% | 34.17% | 58.19% | 73.11% | 73.11% | 73.11% | 73.11% | 73.11% |
|
Syngene
SYNGENE
|
169.26B Mid-cap | 0.89% | -0.12% | 10.57% | -31.32% | -30.25% | -29.79% | -38.23% | -19.99% | 131.38% | 186.56% | 186.56% |
|
Vijaya Diagnostic
VIJAYA
|
109.64B Mid-cap | -1.87% | -3.46% | 36.74% | 29.74% | 23.10% | 35.44% | 216.81% | 105.30% | 105.30% | 105.30% | 105.30% |
|
Metropolis
METROPOLIS
|
97.90B Mid-cap | -0.71% | -0.56% | 14.36% | 9.60% | 10.90% | 24.89% | 56.99% | -23.14% | 118.75% | 118.75% | 118.75% |
|
Thyrocare
THYROCARE
|
62.88B Mid-cap | -1.06% | 15.89% | 48.78% | 23.90% | 19.90% | 55.33% | 231.85% | 23.21% | 170.47% | 153.71% | 153.71% |
Ownership & Short Interest
Calculate Your Dr. Lal PathLabs Investment Returns
Long-Term Investment Performance Analysis
Dr. Lal PathLabs stock price in Jul 2016 was ₹489.48, A ₹1,000.00 lump sum investment in Dr. Lal PathLabs made 9 years ago would be worth approximately ₹3,301.46 today, representing a outstanding return of 230.15%. This translates to an annualized return (CAGR) of 12.81%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is LALPATHLAB's 52-week high and low?
- In the last 52 weeks, Dr. Lal PathLabs reached a high of ₹1,770.00 (on N/A) and a low of ₹1,272.60 (on March 23, 2026).
- What is the market cap and P/E ratio for LALPATHLAB?
- Curious about Dr. Lal PathLabs's size and valuation? Its market capitalization stands at 238.92B. When it comes to valuation, the P/E ratio (trailing twelve months) is 46.16, and the forward P/E (looking ahead) is 41.23.
- Does LALPATHLAB pay dividends? If so, what's the yield?
- Yes, Dr. Lal PathLabs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.56%, and the company has paid an average of ₹23.50 per share annually over the past 3 years.
- Who are Dr. Lal PathLabs's main competitors or similar companies to consider before investing?
When looking at Dr. Lal PathLabs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sai Life Sciences
SAILIFE217.06B Healthcare Diagnostics & Research 58.19% 73.11% Syngene
SYNGENE169.26B Healthcare Diagnostics & Research -29.79% -38.23% Vijaya Diagnostic
VIJAYA109.64B Healthcare Diagnostics & Research 35.44% 216.81% Metropolis
METROPOLIS97.90B Healthcare Diagnostics & Research 24.89% 56.99% Thyrocare
THYROCARE62.88B Healthcare Diagnostics & Research 55.33% 231.85% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dr. Lal PathLabs Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Dr. Lal PathLabs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 22.08%, the Debt to Equity ratio from the most recent quarter is 6.44, and its Gross Profit Margin stands at 65.97%.
- What is the recent revenue and earnings growth for LALPATHLAB?
- Looking at Dr. Lal PathLabs's growth, its revenue over the trailing twelve months (TTM) was INR27B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.60%, and quarterly earnings saw a YoY growth of -6.40%.
- How much of LALPATHLAB stock is held by insiders and institutions?
- Wondering who owns Dr. Lal PathLabs stock? Company insiders (like executives and directors) hold about 54.91% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 31.54%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.